TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29643261

Group type: EXPERIMENTAL
Intervention: EmboTrap device
Number of subjects: 227
Study: 26612341

Group type: EXPERIMENTAL
Intervention: Vitamin C, E, and Ferulic acid serum
Number of subjects: 15

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 15
Study: 25149412

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU intranasal single dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22234020

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 mcg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study: 20107454

Group type: EXPERIMENTAL
Intervention: BOUNCE intervention (12-week exercise, nutrition education, and counseling)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 46
Study: 17585031

Group type: EXPERIMENTAL
Intervention: Walnut-enriched meat (WM)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control meat (CM)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 23
Study: 15324450

Group type: EXPERIMENTAL
Intervention: Direct booking system for colposcopy clinic
Number of subjects: 0
Study: 10936912

Group type: EXPERIMENTAL
Intervention: Auditory localization ability in RM
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Visual localization ability in RM
Number of subjects: 1

Group type: COMPARATOR
Intervention: Auditory localization ability in controls
Number of subjects: 1

Group type: COMPARATOR
Intervention: Visual localization ability in controls
Number of subjects: 1
Study: 9024174

Group type: EXPERIMENTAL
Intervention: DuP 532 (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losartan (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DuP 532 and Losartan (24 hours after dosing)
Number of subjects: 0
Study: 8298200

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 6457
Study: 3477986

Group type: EXPERIMENTAL
Intervention: Local oestriol treatment for 3 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (similar ointment without oestriol) for 3 weeks
Number of subjects: 14
Study: 30631386

Group type: EXPERIMENTAL
Intervention: FNB with 15 ml of lidocaine with epinephrine (300 mg) and 3 ml of MgS 15% (450 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: FNB with 15 ml of lidocaine with epinephrine (300 mg) and 3 ml of normal saline solution
Number of subjects: 48
Study: 27124458

Group type: EXPERIMENTAL
Intervention: Door-to-door canvassing intervention encouraging active perspective-taking
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Door-to-door canvassing intervention
Number of subjects: 501
Study: 25081522

Group type: EXPERIMENTAL
Intervention: Transepithelial PRK (t-PRK)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Mechanical PRK (m-PRK)
Number of subjects: 42
Study: 22882566

Group type: EXPERIMENTAL
Intervention: Probiotic intervention
Number of subjects: 3758

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 3758
Study: 21095287

Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy followed by direct stenting (TS)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Standard balloon predilatation followed by stent implantation (Control)
Number of subjects: 196
Study: 17917738

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg/0.05 ml, three injections at 6-week intervals
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Combined intravitreal bevacizumab (IVB) and triamcinolone (IVT) 1.25 mg/0.05 ml and 2 mg/0.05 ml respectively, followed by two injections of IVB at 6-week intervals
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sham injection (control group)
Number of subjects: 101
Study: 15910477

Group type: COMPARATOR
Intervention: Calcium hydroxide lining
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Conditioning-and-sealing with a smear-removing bonding system
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Composite resin restorations
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Amalgam restorations
Number of subjects: 602
Study: 12930925

Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 1572

Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 1572
Study: 10904662

Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study: 8843231

Group type: EXPERIMENTAL
Intervention: Immunization with p24-VLP
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 1633902

Group type: EXPERIMENTAL
Intervention: Aspiration only
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aspiration and flushing
Number of subjects: 100
Study: 6090530

Group type: EXPERIMENTAL
Intervention: Exogenous glucagon
Number of subjects: 18
Study: 31726314

Group type: EXPERIMENTAL
Intervention: Claims-based follow-up
Number of subjects: 5839

Group type: COMPARATOR
Intervention: Site-based follow-up (+CEC)
Number of subjects: 5839

Group type: EXPERIMENTAL
Intervention: Combined claims and site-based follow-up
Number of subjects: 5839
Study: 29873004

Group type: EXPERIMENTAL
Intervention: Higher starting dose of basal insulin glargine (0.3 U/kg)
Number of subjects: 880

Group type: COMPARATOR
Intervention: Standard starting dose of basal insulin glargine (0.2 U/kg)
Number of subjects: 880
Study: 27346552

Group type: EXPERIMENTAL
Intervention: Low-dose oral vitamin K (LDVK) 150 mcg daily for six months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for six months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose oral vitamin K (LDVK)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25152504

Group type: EXPERIMENTAL
Intervention: Promotion of healthy eating and physical activity
Number of subjects: 565

Group type: COMPARATOR
Intervention: Promotion of breast and cervical cancer screening
Number of subjects: 565
Study: 22167126

Group type: EXPERIMENTAL
Intervention: Overnight modest hyperinsulinaemia (average ≈ 286 pmol/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marked hyperinsulinaemia during the clamp (average steady-state insulin ≈ 900 pmol/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in MBV during the clamp
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MBV after 30 min of marked hyperinsulinaemia
Number of subjects: 0
Study: 19330830

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 316

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 316

Group type: COMPARATOR
Intervention: No chemoradiation
Number of subjects: 316
Study: 17484484

Group type: EXPERIMENTAL
Intervention: 80 watt KTP-laser treatment for small adenomas
Number of subjects: 230

Group type: COMPARATOR
Intervention: Combined treatment of KTP-laser and TUR-P for great adenomas
Number of subjects: 230
Study: 14666737

Group type: COMPARATOR
Intervention: Placebo chewing gum (0.0% Na Hex)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2.0% sodium hexametaphosphate (Na Hex) chewing gum
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3.0% sodium hexametaphosphate (Na Hex) chewing gum
Number of subjects: 12

Group type: COMPARATOR
Intervention: No gum
Number of subjects: 12
Study: 11053913

Group type: EXPERIMENTAL
Intervention: Azelaic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soy extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycolic acid
Number of subjects: 0
Study: 8855542

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Urokinase (UK)
Number of subjects: 40
Study: 1614055

Group type: EXPERIMENTAL
Intervention: AluKart combined with F‐120 or FH‐160 membrane
Number of subjects: 6

Group type: COMPARATOR
Intervention: High‐flux F‐60 polysulfone membrane
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: AluKart combined with FH‐160
Number of subjects: 6
Study: 6233917

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 30
Study: 31111235

Group type: EXPERIMENTAL
Intervention: Statin treatment for primary prevention of ASCVD in patients older than 75 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin treatment for secondary prevention of ASCVD in patients older than 75 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin treatment initiation before 75-80 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinuation of statin treatment when palliative treatment starts
Number of subjects: 0
Study: 28095849

Group type: EXPERIMENTAL
Intervention: Advanced alert method (moving average weight algorithm or bio-impedance cumulative sum algorithm)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Simple alert method (increase of 2 kg in the past 3 days)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Bio-impedance arm (part of advanced alert methods)
Number of subjects: 91
Study: 24816164

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg kg(‐1))
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 23578453

Group type: EXPERIMENTAL
Intervention: Multimodal-antiemetic therapy (group M) including target-controlled infusion of propofol and remifentanil, prophylactic dexamethasone 10 mg, tropisetron 4 mg, and parecoxib sodium 40 mg 30 minutes before the end of surgery
Number of subjects: 129

Group type: COMPARATOR
Intervention: Ondansetron control (group C) including sevoflurane and 50% nitrous oxide, prophylactic ondansetron 4 mg 30 minutes before the end of surgery
Number of subjects: 129
Study: 20697267

Group type: EXPERIMENTAL
Intervention: Walking program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 0
Study: 19799471

Group type: EXPERIMENTAL
Intervention: Duodenal levodopa infusion (DLI)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional oral therapy
Number of subjects: 24
Study: 17101894

Group type: EXPERIMENTAL
Intervention: African American women
Number of subjects: 547

Group type: COMPARATOR
Intervention: White women
Number of subjects: 547

Group type: COMPARATOR
Intervention: African American men
Number of subjects: 547

Group type: COMPARATOR
Intervention: White men
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: African American women (younger than 65 years)
Number of subjects: 547

Group type: COMPARATOR
Intervention: White women (younger than 65 years)
Number of subjects: 547

Group type: COMPARATOR
Intervention: African American men (younger than 65 years)
Number of subjects: 547

Group type: COMPARATOR
Intervention: White men (younger than 65 years)
Number of subjects: 547
Study: 16945766

Group type: EXPERIMENTAL
Intervention: Adjuvant vinorelbine plus cisplatin (30 mg/m² vinorelbine plus 100 mg/m² cisplatin)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 840
Study: 10394407

Group type: EXPERIMENTAL
Intervention: 3-D conformal photon radiotherapy at a dose of 66 Gy
Number of subjects: 291
Study: 8871870

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b (5 MU m-2, then 3 MU m-2 three times weekly for 12 or 24 months)
Number of subjects: 26
Study: 1996795

Group type: EXPERIMENTAL
Intervention: 10 g milk chocolate‐charcoal mixture
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10 g SuperChar Liquid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10 g Actidose Aqua activated charcoal
Number of subjects: 6

Group type: COMPARATOR
Intervention: SuperChar Liquid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: milk chocolate‐charcoal mixture
Number of subjects: 6
Study: 6350078

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Chlorpropamide
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 286

Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Diet plus insulin
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Diet plus chlorpropamide
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Diet plus glibenclamide
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Ultralente insulin
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Insulin and sulphonylurea therapy
Number of subjects: 286
Study: 30768656

Group type: EXPERIMENTAL
Intervention: Tanzania Health Information Technology (T-HIT) system used by health workers at intervention sites for 3 months.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control sites (no specific intervention mentioned).
Number of subjects: 28
Study: 29427602

Group type: EXPERIMENTAL
Intervention: Stress (zip-line ride)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (seated-rest trial)
Number of subjects: 32
Study: 27271831

Group type: EXPERIMENTAL
Intervention: Differential physical rehabilitation program including individual physical therapeutic modalities, static and dynamic respiratory maneuvers, post-isometric relaxation, Vodder's manual lymphatic drainage, and autotraining
Number of subjects: 50

Group type: COMPARATOR
Intervention: Therapeutic physical exercises as described by T.I. Grushina
Number of subjects: 50
Study: 24481686

Group type: EXPERIMENTAL
Intervention: 1-h small-group intervention consisting of facilitated critique of five-step framework, strategies, and pre-recorded modelled role-play.
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 107
Study: 22081522

Group type: EXPERIMENTAL
Intervention: Asacol 2.4 g once daily (OD)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Asacol 800 mg three times daily (TDS)
Number of subjects: 213
Study: 20206793

Group type: EXPERIMENTAL
Intervention: Test formulation of oral piroxicam 20 mg
Number of subjects: 28
Study: 18360335

Group type: EXPERIMENTAL
Intervention: Midazolam plus fentanyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 0
Study: 15924753

Group type: EXPERIMENTAL
Intervention: Surfactant (Curosurf) 200 mg/kg initial dose, repeated doses of 200, 100, and 100 mg/kg at 6-12 hour intervals, maximum of four doses if OI deteriorated by > 2 from baseline
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Surfactant (Curosurf)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 12813474

Group type: EXPERIMENTAL
Intervention: Oral hydrocortisone 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Corticosteroid synthesis inhibitor metyrapone 1500 mg orally
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: No premedication
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Methamphetamine 0.5 mg/kg
Number of subjects: 8
Study: 10585796

Group type: EXPERIMENTAL
Intervention: Low doses of co-trimoxazole
Number of subjects: 521

Group type: COMPARATOR
Intervention: High doses of co-trimoxazole
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 521
Study: 8838489

Group type: EXPERIMENTAL
Intervention: Uniject
Number of subjects: 480

Group type: COMPARATOR
Intervention: Standard Syringe
Number of subjects: 480
Study: 1654967

Group type: EXPERIMENTAL
Intervention: Pipecuronium 0.1 mg kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tubocurarine 0.5 mg kg‐1
Number of subjects: 20
Study: 31037449

Group type: EXPERIMENTAL
Intervention: Usual dose rabeprazole (10 mg/day) + HST (7.5 g/day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Double dose rabeprazole (20 mg/day)
Number of subjects: 78
Study: 28002695

Group type: EXPERIMENTAL
Intervention: Sof‐Lex XT (Sof) with Clearfil SE bond (CS)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sof‐Lex XT (Sof) with Xeno V (XE)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Enhance/Pogo (EP) with Clearfil SE bond (CS)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Enhance/Pogo (EP) with Xeno V (XE)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sof‐Lex XT (Sof)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Clearfil SE bond (CS)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Xeno V (XE)
Number of subjects: 35
Study: 26431793

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 764

Group type: COMPARATOR
Intervention: Oral antipsychotics
Number of subjects: 764
Study: 23628107

Group type: EXPERIMENTAL
Intervention: Online information brochure on fertility
Number of subjects: 137

Group type: COMPARATOR
Intervention: Online information brochure on home ownership
Number of subjects: 137
Study: 21993580

Group type: EXPERIMENTAL
Intervention: Hormone therapy (estradiol associated with trimegestone)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19447518

Group type: EXPERIMENTAL
Intervention: Albinterferon 900 or 1200 microg q2wk, or 1200 microg q4wk
Number of subjects: 458

Group type: COMPARATOR
Intervention: Peginterferon 180 microg qwk
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Albinterferon
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Sequential prediction algorithm based on viral kinetics at weeks 2 and 4
Number of subjects: 458
Study: 17901791

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 738

Group type: COMPARATOR
Intervention: Comparator (amoxicillin/clavulanate, ceftriaxone, clarithromycin, or erythromycin lactobinate)
Number of subjects: 738

Group type: COMPARATOR
Intervention: Comparator
Number of subjects: 738
Study: 15007122

Group type: EXPERIMENTAL
Intervention: L-Dopa
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 11587175

Group type: EXPERIMENTAL
Intervention: Hang-back recession (n=15)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional recession (n=15)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Hang-back recession (n=12)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional recession (n=12)
Number of subjects: 54
Study: 9673298

Group type: EXPERIMENTAL
Intervention: Recombinant Borrelia burgdorferi outer-surface lipoprotein A (OspA) with adjuvant
Number of subjects: 10936

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10936
Study: 8078953

Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine per day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 150 mg amitriptyline per day
Number of subjects: 24
Study: 2688529

Group type: EXPERIMENTAL
Intervention: Iopromide 370 mgI/ml
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ioxaglate 320 mgI/ml
Number of subjects: 24
Study: 164489

Group type: EXPERIMENTAL
Intervention: Positive presleep condition
Number of subjects: 45

Group type: COMPARATOR
Intervention: Negative (stress) presleep condition
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dreaming overtly or symbolically of the presleep laboratory situation
Number of subjects: 45
Study: 29959901

Group type: EXPERIMENTAL
Intervention: Oral contraceptives 1 (20μg EE/150μg desogestrel)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Oral contraceptives 2 (30μg EE/3mg drospirenone)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Oral contraceptives 1 and 2
Number of subjects: 178
Study: 28035636

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) over rVLPFC
Number of subjects: 79

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 79
Study: 26628523

Group type: EXPERIMENTAL
Intervention: Pain exposure physical therapy (PEPT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 56
Study: 23789215

Group type: COMPARATOR
Intervention: Blood-activating and damp-eliminating group
Number of subjects: 160

Group type: COMPARATOR
Intervention: Invigorating and promoting Qi group
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Acupoint-combination stimulation group
Number of subjects: 160
Study: 21671752

Group type: EXPERIMENTAL
Intervention: DPI-C (dry powder inhaler with ∼10% less of each drug per metered dose)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: DPI-C
Number of subjects: 19

Group type: COMPARATOR
Intervention: DPI-A (Advair Diskus®, GlaxoSmithKline, delivering 100 μg fluticasone propionate and 50 μg salmeterol)
Number of subjects: 19
Study: 18213738

Group type: EXPERIMENTAL
Intervention: Tryptophan (serotonin) depletion (ATD)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tyrosine/phenylalanine (dopamine) depletion (ATPD)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combined tryptophan/tyrosine/phenylalanine (CMD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (balanced amino acid drink)
Number of subjects: 14
Study: 16935126

Group type: EXPERIMENTAL
Intervention: Surface-modified cardiopulmonary bypass circuits
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard unmodified circuit
Number of subjects: 69
Study: 14612256

Group type: EXPERIMENTAL
Intervention: resident‐faculty
Number of subjects: 0

Group type: COMPARATOR
Intervention: faculty‐faculty
Number of subjects: 0

Group type: COMPARATOR
Intervention: resident‐faculty‐faculty
Number of subjects: 0
Study: 11015169

Group type: EXPERIMENTAL
Intervention: Statin therapy (3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower LDL cholesterol levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive lipid‐lowering strategies
Number of subjects: 0
Study: 8730243

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg b.d.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Naproxen 500 mg b.d.
Number of subjects: 18
Study: 1382255

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and radiotherapy (3 courses of chemotherapy with cisplatin 100 mg/m2, day 1 and etoposide 125 mg/m2 i.v., day 1; 250 mg/m2 p.o., day 2-3, followed by radiotherapy 4,000 cGy/20 fractions/4 weeks)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 119
Study: 2580182

Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Captopril + Propranolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Captopril + Propranolol + Diuretic
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Captopril + Nifedipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Captopril alone
Number of subjects: 12